Karyopharm Therapeutics Inc.
No enriched coverage for $KPTI in the last 7 days.
Karyopharm Therapeutics Inc. (KPTI) shares fell about 68% after the company reported topline results from its Phase 3 XPORT-EC-042 trial. The trial did not meet its primary endpoint of progression-free survival. The stock dropped 68.17% to $2.2350 on Nasdaq from $7.01 prior close.
Karyopharm Therapeutics (KPTI) reported topline results from its Phase 3 XPORT-EC-042 trial of selinexor as maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer. The trial missed the primary endpoint for progression-free survival, though median PFS was 12.75 months vs 7.43 months with placebo in 236 patients. No new safety signals were reported; full data planned for a medical meeting.
Karyopharm Therapeutics shares fell about 67% to $2.29 after its Phase 3 XPORT-EC-042 endometrial cancer trial missed its primary goal, with no statistically significant progression-free survival improvement versus placebo. Analysts downgraded and cut price targets (e.g., Baird $15 to $3, H.C. Wainwright $13 to $3). Karyopharm said it will scale back endometrial plans and focus on myelofibrosis and multiple myeloma.
Recent KPTI coverage spans financial news, market movers and earnings.
In the last 30 days, KPTI insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1K). The most active reporter was Poulton Stuart, EVP, Chief Development Officer, with 1 filing.
Trial failure likely drives sharp de-risking of the lead program and raises probability of future financing or strategy changes.
Endpoint miss with a non-significant but favorable PFS trend likely pressures near-term sentiment and valuation, while longer follow-up and other milestones keep optionality alive.
Trial failure and pipeline devaluation dominate near-term valuation, while an August 2026 supplemental NDA for selinexor plus ruxolitinib offers only partial offset.
Regulatory-pathway milestone increases probability of an accelerated approval decision and near-term valuation sensitivity to FDA review progress.
Retention cash awards and potential clawback terms are a modest, mostly balance-sheet and governance signal rather than an operational catalyst.
alphai scores every news story that mentions KPTI with an AI model for sentiment and relevance, and aggregates insider trades from Karyopharm Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Karyopharm Therapeutics Inc. (KPTI) shares fell about 68% after the company reported topline results from its Phase 3 XPORT-EC-042 trial. The trial did not meet its primary endpoint of progression-free survival. The stock dropped 68.17% to $2.2350 on Nasdaq from $7.01 prior close.
2 min readKaryopharm Therapeutics (KPTI) reported topline results from its Phase 3 XPORT-EC-042 trial of selinexor as maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer. The trial missed the primary endpoint for progression-free survival, though median PFS was 12.75 months vs 7.43 months with placebo in 236 patients. No new safety signals were reported; full data planned for a medical meeting.
3 min readKaryopharm Therapeutics shares fell about 67% to $2.29 after its Phase 3 XPORT-EC-042 endometrial cancer trial missed its primary goal, with no statistically significant progression-free survival improvement versus placebo. Analysts downgraded and cut price targets (e.g., Baird $15 to $3, H.C. Wainwright $13 to $3). Karyopharm said it will scale back endometrial plans and focus on myelofibrosis and multiple myeloma.
4 min read– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results – – Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit – – If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the...
4 min readKaryopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001503802 0001503802 2026-07-13 2026-07-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 20
2 min readIs it a good or bad thing when a stock experiences a golden cross technical event?
3 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
3 min readKaryopharm Therapeutics Inc. ( NASDAQ:KPTI ) on Wednesday announced comprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility and additional capital, extending the cash runway into the second quarter of 2026.
2 min readKaryopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readKaryopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 min read
